Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 - 2015)

Date: August 22, 2011
Pages: 65
Price:
US$ 850.00
License [?]:
Publisher: Renub Research
Report type: Strategic Report
Delivery: E-mail Delivery (Word), CD-ROM Mail Delivery, Online Subscription, Hard Copy Mail Delivery, E-mail Delivery (PDF)
ID: G9EB2FDC4A5EN
Leaflet:

Download PDF Leaflet

Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 - 2015)
Schizophrenia is a mental disorder characterized by disintegration of thought processes and of emotional responsiveness. It most commonly manifests as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, or lack of concentration and motivation and it is accompanied by significant social or occupational dysfunction. However with proper medication this disease can be contained to a great extent and Schizophrenia patients can lead a normal healthy life style.

At present lot of drugs for Schizophrenia are available in the market. From the introduction of Clozapine in 1991.Since, 1960, the first atypical antipsychotic to treat schizophrenia, the growth of this class has been rapid. Zyprexa, Seroquel, Risperdal, Abilify, Geodon are the blockbuster drug which has changed the dynamics of the schizophrenia market. But the major worry for the manufactures of these drugs is that by 2011 and 2012 almost all the major blockbuster drugs are going off-patent.

However, depot formulation is the emerging segment which has long term chances of success. The pipeline drug like Lurasidone, Staccato, Cariprazine, Pimavanserin have the comparable efficacy and a similar mechanism of action to that of the existing brands which will enter the market by 2011.

Report Details

“Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 – 2015)” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally and features latest available data covering
  • Global Schizophrenia Market has been covered from 2004-2019
  • Global Schizophrenia patients in 7 countries
  • Top 10 Schizophrenia Drug Brands (Zyprexa, Seroquel, Risperdal, Abilify, Geodon, Lonasen, Serdolect, Invega, Fanapt, Saphris) data analysis of Past, Present and Future Market
  • Top 3 Schizophrenia Depot Formulations Brands (Risperdal Consta, Invega Sustenna, Relprevv) data analysis of Past, Present and Future Market
  • Pipeline Developmental Agents (Lurasidone, Staccato, Cariprazine, Pimavanserin) Future Trends Analyis
  • Key Companies Strengths and Weakness analysis in Global Schizophrenia
Research Highlights
  • The prevalence of Schizophrenia in United States is expected to reach nearly 4 Million by 2020
  • From 2012 onwards Schizophrenia market is expected to show a decline
  • Zyprexa is the most successful product in the history of neuroscience
  • Abilify hit blockbuster sales in 2006 and it is anticipated that sales will cross US$ 2.5 Billion by 2014.
  • Risperdal Consta is the blockbuster injectable form of medicines and predicted that the sale will cross US$ 2 Billion by 2014
  • Lurasidone, Staccato, Cariprazine, Pimavanserin are the pipepline drug which will be launched by 2011
Key Companies Analyzed

This section covers the business description, Strengths and Weakness of major players in Global Schizophrenia Market. The key players analyzed in this section are – Eli Lilly and Company, AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb and Pfizer.

Data Sources

Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.
1. EXECUTIVE SUMMARY

2. GLOBAL SCHIZOPHRENIA MARKET PAST, PRESENT & FUTURE TREND

3. PREVALENCE OF SCHIZOPHRENIA IN TOP 7 COUNTRIES

3.1 United States of America
  3.1.1 Schizophrenia Population & Future Scenario
3.2 Japan
  3.2.1 Schizophrenia Population & Future Scenario
3.3 Germany
  3.3.1 Schizophrenia Population & Future Scenario
3.4 France
  3.4.1 Schizophrenia Population & Future Scenario
3.5 Italy
  3.5.1 Schizophrenia Population & Future Scenario
3.6 United Kingdom
  3.6.1 Schizophrenia Population & Future Scenario
3.7 Spain
  3.7.1 Schizophrenia Population & Future Scenario

4. GLOBAL – TOP 10 SCHIZOPHRENIA DRUG BRANDS MARKET PERFORMANCE

4.1 Zyprexa (Olanzapine)
4.2 Seroquel (Quetiapine)
4.3 Geodon
4.4 Risperdal (Risperidone)
4.5 Lonasen
4.6 Serdolect
4.7 Abilify (Aripiprazole)
4.8 Invega (Paliperidone)
4.9 Fanapt (iloperidone)
4.10 Saphris (Asenapine)

5. GLOBAL – TOP 3 SCHIZOPHRENIA DEPOT FORMULATIONS BRAND MARKET PERFORMANCE

5.1 Risperdal Consta (Risperidone)
5.2 Invega Sustenna (Paliperidone Palmitate)
5.3 Relprevv/Zyphdera (Olanzapine LAI)

6. PIPELINE DEVELOPMENTAL AGENTS – FUTURE TRENDS

6.1 Lurasidone
6.2 Staccato (Loxapine Inhalation)
6.3 Cariprazine (RGH-188)
6.4 Pimavanserin

7. KEY COMPANIES

7.1 Eli Lilly and Company
  7.1.1 Business Description
  7.1.2 Strength & Weaknesses
7.2 Astrazeneca
  7.2.1 Business Description
  7.2.2 Strength & Weaknesses
7.3 Johnson & Johnson
  7.3.1 Business Description
  7.3.2 Strength & Weaknesses
7.4 Bristol-Myers Squibb
  7.4.1 Business Description
  7.4.2 Strength & Weaknesses
7.5 Pfizer
  7.5.1 Business Description
  7.5.2 Strength & Weaknesses

LIST OF FIGURE:

Figure 2 1: Global – Schizophrenia Market (Billion US$), 2004 – 2010
Figure 2 2: Global – Forecast for Schizophrenia Market (Billion US$), 2011 – 2019
Figure 3 1: USA – Number of Patients with Schizophrenia Disease (Million), 2005 – 2010
Figure 3 2: Japan – Number of Patients with Schizophrenia Disease (Million), 2005 – 2010
Figure 3 3: Germany – Number of Patients with Schizophrenia Disease (Million), 2005 – 2010
Figure 3 4: France – Number of Patients with Schizophrenia Disease (Million), 2005 – 2010
Figure 3 5: Italy – Number of Patients with Schizophrenia Disease (Million), 2005 – 2010
Figure 3 6: UK – Number of Patients with Schizophrenia Disease (Million), 2005 – 2010
Figure 3 7: Spain – Number of Patients with Schizophrenia Disease (Million), 2005 – 2010
Figure 4 1: Global – Zyprexa Drug Sales (Million US$), 1999 – 2010
Figure 4 2: Global – Forecast for Zyprexa Drug Sales (Million US$), 2011 – 2015
Figure 4 3: Global – Seroquel Drug Sales (Million US$), 1999 – 2010
Figure 4 4: Global – Forecast for Seroquel Drug Sales (Million US$), 2011 – 2015
Figure 4 5: Global – Geodon Drug Sales (Million US$), 1999 – 2010
Figure 4 6: Global – Forecast for Geodon Drug Sales (Million US$), 2011 – 2015
Figure 4 7: Global – Risperdal Drug Sales (Million US$), 1999 – 2010
Figure 4 8: Global – Forecast for Risperdal Drug Sales (Million US$), 2011 – 2015
Figure 4 9: Global – Lonasen Drug Sales (Million US$), 2008 – 2010
Figure 4 10: Global – Forecast for Lonasen Drug Sales (Million US$), 2011 – 2014
Figure 4 11: Global – Serdolect Drug Sales (Million US$), 2006 – 2010
Figure 4 12: Global – Forecast for Serdolect Drug Sales (Million US$), 2011 – 2015
Figure 4 13: Global – Abilify Drug Sales (Million US$), 2002 – 2010
Figure 4 14: Global – Forecast for Abilify Drug Sales (Million US$), Q1-2011, 2011 – 2015
Figure 4 15: Global – Invega Drug Sales (Million US$), 2008 – 2010
Figure 4 16: Global – Forecast for Invega Drug Sales (Million US$), 2011 – 2015
Figure 4 17: Global – Forecast for Fanapt Drug Sales (Million US$), 2011 – 2015
Figure 4 18: Global – Forecast for Saphris Drug Sales (Million US$), 2011 – 2015
Figure 5 1: Global – Risperdal Consta Drug Sales (Million US$), 2006 – 2010
Figure 5 2: Global – Forecast for Risperdal Consta Drug Sales (Million US$), 2011 – 2015
Figure 5 3: Global – Invega Sustenna Drug Sales (Million US$), 2009 – 2010
Figure 5 4: Global – Forecast for Invega Sustenna Drug Sales (Million US$), 2011 – 2015
Figure 5 5: Global – Relprevv/Zyphdera Drug Sales (Million US$), 2009 – 2010
Figure 5 6: Global – Forecast for Relprevv/Zyphdera Drug Sales (Million US$), 2011 – 2015
Figure 6 1: Global – Forecast for Lurasidone Drug Sales (Million US$), 2011 – 2017
Figure 6 2: Global – Forecast for Staccato Drug Sales (Million US$), 2010 – 2017
Figure 6 3: Global – Forecast for Cariprazine Drug Sales (Million US$), 2013 – 2017
Figure 6 4: Global – Forecast for Pimavanserin Drug Sales (Million US$), 2014 – 2017

LIST OF TABLES:

Table 3 1: USA – Forecast for Number of Patients with Schizophrenia Disease (Million), 2010 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 2: Japan – Forecast for Number of Patients with Schizophrenia Disease (Million), 2010 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 3: Germany – Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 4: France – Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 5: Italy – Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 6: UK – Forecast for Number of Patients with Schizophrenia Disease (Million), 2010 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 7: Spain – Forecast for Number of Patients with Schizophrenia Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 4 1: Eli Lilly – Challenges to Zyprexa Patents in a number of Countries outside the U.S (2007, 2008 & 2010)
Table 7 1: Eli Lilly and Company – Key Financial (Million US$), 2008 – 2010
Table 7 2: Astrazeneca – Key Financial (Million US$), 2008 – 2010
Table 7 3: Johnson & Johnson – Key Financial (Million US$) 2008 – 2010
Table 7 4: Bristol-Myers Squibb – Key Financial (Million US$) 2008 – 2010
Table 7 5: Global – Comparison Chart of Patent Expiry Date of different Blockbuster Drugs
Table 7 6: Pfizer – Key Financial (Million US$), 2008 – 2010
Skip to top


Ask Your Question

Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 - 2015)
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: